In one of the largest studies to measure the burden of antibiotic resistance in a low- or middle-income country, researchers at the Center for Disease Dynamics, Economics & Policy report that in-hospital mortality is significantly higher among patients infected with multi-drug resistant (MDR) or extensively drug resistant (XDR) pathogens including Staphylococcus aureus, Escherichia coli, Klebsiella […]Continue Reading ...
Before patients receive intravenous (IV) antimicrobial infusion therapy outside of the hospital—whether at home, a doctor’s office or a skilled nursing facility—an infectious diseases (ID) specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America (IDSA). Once they begin receiving outpatient parenteral antimicrobial […]Continue Reading ...
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center. Findings from the study, led by […]Continue Reading ...
How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomized trials where patients are randomly divided into two groups: one of the groups is given treatment, and the other a placebo. Is this really the only reliable way to evaluate treatment effectiveness, or […]Continue Reading ...
(HealthDay)—Centralized pain pathways may coexist with more established peripheral inflammation-driven pathways in some patients with rheumatoid arthritis (RA), according to a study published in the July issue of Arthritis & Rheumatology. Neil Basu, M.D., Ph.D., from the University of Aberdeen in the United Kingdom, and colleagues performed an 11-minute functional connectivity magnetic resonance imaging (MRI) […]Continue Reading ...
Oregon State University researchers have discovered two key factors behind the intestinal inflammation that plagues people suffering from a disorder that affects their immune system. The findings, published in Clinical Immunology, are important because common variable immunodeficiency, known as CVID, afflicts hundreds of thousands of people worldwide. A significant proportion of them will have potentially […]Continue Reading ...
An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel. Results from the phase I clinical trial of the drug, called ZW25, had been […]Continue Reading ...
WEDNESDAY, Nov. 7, 2018 — For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival is longer in those receiving the immunostimulatory monoclonal antibody elotuzumab in addition to pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone, according to a study published in the Nov. 8 issue of […]Continue Reading ...
Breakthrough study shows that radiotherapy toxicity might be reduced by ‘personalized scheduling’ A new clinical study led by the University of Leicester and conducted in the HOPE clinical trials facility at Leicester’s Hospitals has revealed the pivotal role that changing the time of day that a patient receives radiotherapy could play in altering radiotherapy toxicity. […]Continue Reading ...
Before patients receive intravenous (IV) antimicrobial infusion therapy outside of the hospital – whether at home, a doctor’s office or a skilled nursing facility – an infectious diseases (ID) specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America (IDSA). Once they begin […]Continue Reading ...
An international study published in the journal Blood by researchers led by Dr. Elie Haddad, a pediatric immunologist and researcher at CHU Sainte-Justine and professor at Université de Montréal, highlights the urgent need to develop better treatment strategies for patients suffering from severe combined immune deficiency (SCID). This deficiency, better known as “bubble baby disease” […]Continue Reading ...
(HealthDay)—There’s bad news for heart failure patients with dilated cardiomyopathy who’d like to stop taking their meds. Any progress they’ve seen on medication is likely to fade once they stop taking their heart drugs, new clinical trial results show. About 40 percent of a small group of patients wound up back on their medications after […]Continue Reading ...
New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer. Professor Laura van ‘t Veer, leader of the Breast Oncology Program at the University of California […]Continue Reading ...
Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults LAVAL, Quebec, Nov. 7, 2018 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced it expects to start distribution of Bryhali (halobetsasol propionate) […]Continue Reading ...
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors (ICIs). The study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as […]Continue Reading ...
- Scientists succeed in increasing stability, biocompatibility of light-transducing nanoparticles
- Sugar, a ‘sweet’ tool to understand brain injuries
- Pharmacist-Led Effort Cuts Inappropriate Rx in Older Adults
- Novel discovery could lead to new cancer, autoimmune disease therapy
- AHA and ADA launch new initiative to help people with type 2 diabetes reduce heart disease risk
- Balanced production of pro and anti-inflammatory cytokines at two years of age protects against malaria
- New pharmacological agent shows promise for prevention of heart rhythm disorders
- All That Social Media May Boost Loneliness, Not Banish It
- Scientists shine new light on link between obesity and cancer
- Risk factors for cardiovascular disease closely track with changes in diet patterns
- Biogen Scoops Sixth Prix Galien Award with UK Win for Life-Changing Rare Disease Medicine
- Detectable HIV-1 in treated human liver cells found to be inert
- Using light to control crucial step in embryonic development
- Unusual case of father-to-son HIV transmission reported
- FDA Approves Aemcolo (rifamycin) to Treat Travelers’ Diarrhea
- Poverty blamed on widening north-south gap in young adult deaths in England
- Progress in meningitis lags far behind other vaccine-preventable diseases, analysis shows
- Consensus Statement Issued on Management of Foot, Ankle Gout
- Fine particle air pollution is a public health emergency hiding in plain sight
- In-hospital mortality higher among patients with drug-resistant infections